The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.
An article from
Dive Brief
The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.
Published Aug. 31, 2026
Jacob Bell/BioPharma Dive
The FDA has approved Takeda’s Mimrylo (rusfertide) for polyc | The FDA has approved Takeda’s Mimrylo (rusfertide) for…
Mimrylo, from Takeda and Protagonist, is a new kind of treatment for the blood cancer polycythemia vera.
FDA approved Takeda & Protagonist's Mimrylo (rusfertide) for polycythemia vera, a rare blood disease.
The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit…
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia…
MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with…
